Deciphera Pharmaceuticals, Llc

This study tests a new drug called DCC-3116 combined with other cancer treatments for people with advanced GIST, a type of stomach or intestinal cancer. The goal is to find safe doses and see if the combination shrinks tumors. About 94 adults whose cancer has worsened after stand…

This early-stage trial is testing a new oral drug called DCC-2812 in 60 people with advanced kidney, bladder, or prostate cancers that have spread. The main goals are to check safety and find the right dose, while also looking for signs that the drug can shrink tumors. It is a fi…

This study tests a new drug called DCC-3009, alone or with other cancer treatments, for people with advanced gastrointestinal stromal tumor (GIST) that has stopped responding to standard therapy. About 120 participants will receive the drug in 28-day cycles for up to 2 years. The…

This study tests whether the drug vimseltinib is safe and effective for adults with moderate to severe chronic graft-versus-host disease (cGVHD) who have not improved after at least two prior treatments. About 48 participants will take vimseltinib daily for up to two years. The g…

This study looks at how a new drug called vimseltinib changes the way the body processes birth control pills. It involves 24 healthy women and lasts about 35 days. The goal is to see if vimseltinib makes birth control less effective, which is important for women who might take th…

This observational study follows 100 people with tenosynovial giant cell tumor (TGCT) who are taking vimseltinib as part of their routine care. Researchers will collect data on how long patients stay on the drug and how it affects their quality of life. The study does not change …